Skip to content

US · FHTX · BIOTECHNOLOGY

Foghorn Therapeutics Inc. (FHTX) intrinsic value and stock valuation

$1.72as of 2026-11-21 · Mkt cap 286.52M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Foghorn Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values FHTX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from FHTX’s statements →

Foghorn Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Watertown, MA 02472 foghorntx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$30.9M+135.1% 5y CAGRd
20182025
Net income
-$-74.28M
20182025
Free cash flow
-$-86.15M
20182025
Total equity
-$-108.5M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$30.9M$22.6M$34.2M$19.2M$1.32M
Operating income-$-82.11M-$-102.68M-$-107.91M-$-117.14M-$-100.73M
Net income-$-74.28M-$-86.62M-$-98.43M-$-108.88M-$-101.32M
EPSd-$-1.18M-$-1.58M-$-2.35M-$-2.62M-$-2.73M
Operating cash flow-$-86.1M-$-100.41M-$-118.11M$193.6M-$-50.25M
Capital expenditure-$-50K-$-910K-$-1.22M-$-1.21M-$-3.31M
Free cash flow-$-86.15M-$-101.31M-$-119.33M$192.4M-$-53.56M
Total assets$198.1M$284M$285.9M$404.9M$519.8M
Total debt$41.3M$37.1M$45.1M$51.5M$58.3M
Net debt-$-39.61M-$-18.32M-$-35.26M-$-710K-$-42.8M
Total equity-$-108.5M-$-45.53M-$-77.19M$110K$96.9M
Cash and short-term investments$158.9M$243.8M$234.1M$345.8M$154.3M
Income statement
20252024202320222021
Revenue$30.9M$22.6M$34.2M$19.2M$1.32M
Cost of revenue$3.33M$0.00$0.00$0.00$0.00
Gross profit$27.6M$22.6M$34.2M$19.2M$1.32M
Research and development expenses$85.5M$94.5M$109.7M$105.6M$80.3M
Selling, general and administrative expenses$27.6M$28.4M$32.4M$30.8M$21.7M
Other expenses-$-3.33M$2.4M$0.00$0.00$0.00
Operating expenses$109.7M$125.3M$142.1M$136.4M$102.1M
Cost and expenses$113M$125.3M$142.1M$136.4M$102.1M
Interest income$8.74M$11.9M$10.9M$5.67M$60K
Interest expense$0.00$0.00$0.00$0.00$1.91M
Depreciation and amortization$3.33M$3.12M$3.45M$3.32M$3.23M
Ebitda-$-70.95M-$-97.17M-$-90.75M-$-105.56M-$-96.19M
Operating income-$-82.11M-$-102.68M-$-107.91M-$-117.14M-$-100.73M
Total other income/expenses, net$7.82M$16.1M$13.7M$8.26M-$-590K
Income before tax-$-74.28M-$-86.62M-$-94.2M-$-108.88M-$-101.32M
Income tax expense$0.00$0.00$4.23M$0.00$0.00
Net income-$-74.28M-$-86.62M-$-98.43M-$-108.88M-$-101.32M
Weighted average shares outstanding$63M$54.9M$42M$41.6M$37.2M
Weighted average diluted shares outstanding$63M$54.9M$42M$41.6M$37.2M
Balance sheet
20252024202320222021
Cash and short-term investments$158.9M$243.8M$234.1M$345.8M$154.3M
Net receivables$0.00$0.00$0.00$0.00$300M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$163.2M$249.6M$240.2M$351.4M$459.6M
Property, plant and equipment, net$32.9M$32.6M$42.9M$49.4M$56.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$34.9M$34.4M$45.7M$53.5M$60.2M
Total assets$198.1M$284M$285.9M$404.9M$519.8M
Accounts payable$4.27M$3.79M$6.26M$5.41M$3.82M
Short-term debt$920K$9.07M$8.52M$5.97M$6.99M
Deferred revenue$43.2M$45.6M$34.6M$32.8M$28.3M
Total current liabilities$59.7M$67M$58.4M$55.2M$48.7M
Long-term debt$40.4M$28.1M$36.6M$45.5M$51.3M
Deferred revenue, non-current$206M$234.5M$268.1M$304M$322.7M
Total non-current liabilities$246.9M$262.5M$304.7M$349.6M$374.2M
Capital lease obligations$41.3M$37.1M$45.1M$51.5M$58.3M
Total liabilities$306.6M$329.5M$363.1M$404.8M$422.9M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-632.47M-$-558.18M-$-471.56M-$-373.14M-$-264.26M
Accumulated other comprehensive income (loss)$20K$140K-$-830K-$-3.99M-$-10K
Total equity-$-108.5M-$-45.53M-$-77.19M$110K$96.9M
Total investments$78M$188.3M$153.7M$293.6M$53.2M
Total debt$41.3M$37.1M$45.1M$51.5M$58.3M
Net debt-$-39.61M-$-18.32M-$-35.26M-$-710K-$-42.8M
Cash flow statement
20252024202320222021
Net income-$-74.28M-$-86.62M-$-98.43M-$-108.88M-$-101.32M
Depreciation and amortization$3.33M$3.12M$3.45M$7.9M$3.23M
Stock-based compensation$10.4M$11.9M$16.2M$0.00$8.38M
Change in working capital-$-32.14M-$-32.27M-$-41.88M$281.6M$33.4M
Accounts receivable$0.00$0.00$0.00$300M-$-300M
Inventory$0.00$0.00$0.00$0.00-$-3.17M
Accounts payable$480K-$-2.48M$850K$1.61M$140K
Net cash provided by operating activities-$-86.1M-$-100.41M-$-118.11M$193.6M-$-50.25M
Investments in property, plant and equipment-$-50K-$-910K-$-1.22M-$-1.21M-$-3.31M
Acquisitions, net$0.00$0.00$0.00$0.00-$-39.49M
Net cash used for investing activities$112M-$-29.9M$144.5M-$-244.32M$36.2M
Common stock issued$1.02M$103.4M$0.00$1.76M$42.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.02M$105.4M$1.78M$1.76M$22.4M
Net change in cash$27M-$-24.88M$28.1M-$-48.92M$8.34M
Cash at end of period$84.1M$57.2M$82M$52.2M$102.9M
Operating cash flow-$-86.1M-$-100.41M-$-118.11M$193.6M-$-50.25M
Capital expenditure-$-50K-$-910K-$-1.22M-$-1.21M-$-3.31M
Free cash flow-$-86.15M-$-101.31M-$-119.33M$192.4M-$-53.56M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Foghorn Therapeutics Inc.

        Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.

        CEO
        Adrian H. Gottschalk
        Employees
        106
        Beta
        2.86

        Explore

        Frequently asked questions

        What is the intrinsic value of Foghorn Therapeutics Inc. (FHTX)?

        Foghorn Therapeutics Inc. (FHTX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is FHTX undervalued?

        FHTX trades at a price of $1.72 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.